Aigul Sartayeva

Dr. Aigul Sartayeva

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2024 in Vascular Health and Risk Management
Verified
Journal Article
Open access
PDF file
NYNurlan Yeshniyazov
Nurlan Yeshniyazov
IPIgor N Posokhov
Igor N Posokhov
VMVadim Medovchshikov
Vadim Medovchshikov
GKGulnara Kurmanalina
Gulnara Kurmanalina
ASAigul Sartayeva
Aigul Sartayeva
The coexistence of heart failure (HF) and type 2 diabetes mellitus (T2DM) is common and poses a serious threat to human health because these diseases have a high degree of commonality at the vascular level. However, the diagnosis of HF in primary care can be challenging, leading to the risk of inadequate management of both conditions. Using two case reports as examples, we attempt to shed light on the issues involved in this challenge. In the first case presentation, a 62-year-old male patient with T2DM and dyspnea was initially diagnosed with HF during primary care. However, further workup revealed that the actual cause of the patient’s breathlessness was the exacerbation of chronic obstructive pulmonary disease. In the second case, a 59-year-old woman with T2DM and obesity complained of leg swelling that was attributed to chronic venous insufficiency by a primary care physician. A correct diagnosis of HF with preserved ejection fraction (HFpEF) was made using N-terminal pro-B-type natriuretic peptide and echocardiography. Due to diabetic vasculopathy HF is more likely to progress with a preserved ejection fraction. In addition, symptoms of COPD or obesity may overlap with or mask symptoms of HFpEF. The issues of over- and misdiagnosis of HFpEF in primary care are discussed in our review, which emphasizes the nonspecific nature of symptoms, such as breathlessness and leg edema in patients with type 2 diabetes mellitus. It is of utmost importance for healthcare providers to be aware of unusual manifestations of heart failure and, vice versa, of diseases that masquerade as heart failure. This will enable them to manage risks in these patients with greater consistency.

25 February 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
LDLaura Danyarova
Laura Danyarova
GSGulnara Svyatova
Gulnara Svyatova
GBGalina Berezina
Galina Berezina
RTRustem Tuleutayev
Rustem Tuleutayev
BSBalnur Sultanova
Balnur Sultanova
Indira KaribayevaIndira Karibayeva
Indira Karibayeva
Background: Gestational diabetes mellitus (GDM) poses a growing public health challenge worldwide due to its increasing prevalence, associated pregnancy complications, and long-term metabolic risks for both mothers and offspring. Genetic factors are known to contribute to GDM susceptibility, yet little is known about their relevance in ethnic Kazakh population. The primary objective of this study was to evaluate associations between selected candidate SNPs involved in β-cell function and the risk of GDM in a Kazakh cohort. Secondary objectives included the assessment of potential gene–gene interactions. Methods: We conducted a case–control study among 365 pregnant Kazakh women. Of these, 217 were diagnosed with GDM, and 148 had normal glucose tolerance. Clinical and genealogical data were collected. Eight candidate SNPs that were previously associated with GDM or glucose metabolism were genotyped. Logistic regression was used to assess associations between SNPs and GDM risk. Gene–gene interactions were evaluated using multifactor dimensionality reduction (MDR). Results: In univariate analysis, MTNR1B rs10830963 demonstrated a statistically significant association under the additive model (OR 0.61, 95% CI 0.42–0.89), indicating a potential protective effect of the C allele. However, this association was not statistically significant after multivariable adjustment (adjusted OR 0.58, 95% CI 0.32–1.03) and correction for multiple testing. In the adjusted analysis, TCF7L2 rs7903146 showed a significant association under the dominant model (adjusted OR 2.29, 95% CI 1.01–5.46); however, this finding did not remain significant following FDR correction. MDR analysis showed that the best two-locus model included IGF2BP2 rs4402960 and CDKAL1 rs7754840 (CVC = 6/10; testing accuracy = 0.558; permutation p < 0.001). The most stable interaction was observed for the three-locus model comprising IGF2BP2 rs4402960, MTNR1B rs10830963, and PPARG rs1801282 (CVC = 9/10; testing accuracy = 0.576; permutation p < 0.001). Conclusions: The findings suggest that common variants in IGF2BP2, CDKAL1, MTNR1B, TCF7L2, PPARG, and GCK do not exert strong individual effects on GDM susceptibility in this cohort of ethnic Kazakh women. Instead, the results are more consistent with a modest polygenic architecture characterized by small effect sizes and possible weak gene–gene interactions. MDR analysis identified statistically significant interaction models; however, their limited predictive accuracy indicates that these findings should be interpreted as exploratory.

27 February 2026 in Наука и здравоохранение
Verified
Journal Article
Open access
PDF file
IKIndira Kaibagarova
Indira Kaibagarova
NANurgul Ablakimova
Nurgul Ablakimova
GSGaziza Smagulova
Gaziza Smagulova
NMNadiya Mavlyudova
Nadiya Mavlyudova
AMAigul Mussina
Aigul Mussina
LZLazzat Zhamaliyeva
Lazzat Zhamaliyeva
Background. Type 2 diabetes mellitus remains one of the leading causes of chronic morbidity and disability, imposing a substantial clinical and economic burden on healthcare systems. In primary health care settings, effective glycemic control largely depends on the rational prescribing of oral hypoglycemic agents, appropriate dosing, and patient adherence to therapy. However, real-world clinical practice often demonstrates deviations of prescribed daily doses from recommended standards, along with persistent barriers related to drug accessibility and financial constraints. This highlights the need to analyze the structure of oral hypoglycemic drug utilization and the factors influencing the achievement of target glycemic outcomes. Aim:to analyze the consumption patterns and therapeutic effectiveness of oral hypoglycemic drugs (OHDs) among patients with T2DM in the primary healthcare system of Aktobe, Kazakhstan, while identifying indirect indicators and possible barriers to glycemic control based on prescription patterns and dosage data. Materials and methods: Data from 386 T2DM patients receiving continuous OHD therapy for at least six months were extracted from the Medical Information System. The analysis focused on drug consumption patterns, defined daily dose (DDD) versus prescribed daily dose (PDD), glycemic outcomes, and comorbidities. HbA1c levels were evaluated to assess treatment effectiveness, while factors influencing therapy adherence and dosing were explored. Results: Metformin was the most prescribed monotherapy (31.9%), and a combination of sulfonylureas and metformin dominated dual therapy (41.7%). Combination therapy was necessary for 59.1% of patients, indicating the limitations of monotherapy in con-trolling glycemia. Combination therapies involving metformin significantly improved HbA1c levels, especially with sulfonylureas (61%, p = 0.003) and SGLT-2 inhibitors (70.5%, p = 0.039). However, the PDDs of all OHDs were markedly below the WHO DDDs, with metformin's PDD 78% lower. Barriers included medication access and financial constraints. Conclusions: Optimizing OHD regimens and addressing medication access challenges are essential to improving glycemic control and reducing T2DM complications in resource-constrained environments. Актуальность: Сахарный диабет 2 типа остается одной из ведущих причин хронической заболеваемости и инвалидизации, формируя значительную клиническую и экономическую нагрузку на систему здравоохранения. В условиях первичной медико-санитарной помощи эффективность контроля гликемии во многом зависит от рационального назначения пероральных сахароснижающих препаратов, адекватности их дозирования и приверженности пациентов терапии. Однако в реальной клинической практике часто наблюдаются отклонения предписанных суточных доз от рекомендованных стандартов, а также сохраняются барьеры, связанные с доступностью лекарств и финансовыми ограничениями. Это определяет необходимость анализа структуры потребления ПССП и факторов, влияющих на достижение целевых показателей гликемии. Цель: Изучение структуры потребления и терапевтической эффективности пероральных сахароснижающих препаратов (ПССП) у пациентов с сахарным диабетом 2 типа (СД2) в системе первичной медико-санитарной помощи г. Актобе, Казахстан, а также выявление факторов, препятствующих достижению оптимального контроля гликемии. Методы: Из медицинской информационной системы были извлечены данные о 386 пациентах с СД2, получавших непрерывную терапию ПССП в течение не менее шести месяцев. Анализ был сосредоточен на структуре потребления лекарств, сравнении определенной суточной дозы (DDD) с предписанной суточной дозой (PDD), гликемических показателях и сопутствующих заболеваниях. Эффективность лечения оценивалась по уровню HbA1c, а также изучались факторы, влияющие на приверженность терапии и дозирование. Результаты:Метформин был наиболее часто назначаемым препаратом в монотерапии (31,9%), тогда как комбинация метформина с препаратами сульфонилмочевины преобладала в двойной терапии (41,7%). Комбинированная терапия применялась у 59,1% пациентов, что указывает на ограниченную эффективность монотерапии в контроле гликемии. Комбинированная терапия с использованием метформина значительно снижала уровень HbA1c, особенно при сочетании с...

31 October 2025 in Astana Medical Journal
Verified
Journal Article
Closed access
WUWest Kazakhstan Marat Ospanov Medical Uiversity
West Kazakhstan Marat Ospanov Medical Uiversity
ASAigul Sartayeva
Aigul Sartayeva
The search for new hypoglycemic agents for the prevention and treatment of type 2 diabetes is driven by the severe burden of this disease on the global population. Type 2 diabetes affects over 500 million adults worldwide and is characterized by a steady increase, despite the impressive arsenal of synthetic hypoglycemic drugs that target various stages of diabetes pathogenesis. Interest in natural complex compounds found in medicinal plants is currently growing. This bibliometric analysis aims to examine the results of studies on the hypoglycemic potential of herbal medicines in the treatment of patients with type 2 diabetes. Data were extracted from the open-access PabMed database using an inclusive search strategy. The analysis included 379 relevant studies published in 180 different sources, involving 1,804 authors. The results show a marked increase in research on the efficacy of herbal remedies, indicating a growing interest in new sources of non-drug approaches to diabetes. Bradford's Law identified 13 key journals that played a significant role in disseminating research in this area, with Medicine emerging as the most prolific. The United States and China were particularly strong in collaborative research. The China Academy of Chinese Medical Sciences, Beijing University of Chinese Medicine, and the Hospital of Chengdu University of Traditional Chinese Medicine were the most productive institutions, and Tong X. and Zhang Y. were the lead authors. A chronological keyword analysis highlighted the significance of terms such as "Humans, female, middle-aged, male, diabetes mellitus type 2, drug therapy." Overall, this study sheds light on the global landscape of research on the use of herbal remedies in patients with type 2 diabetes. The information obtained from this analysis is important for determining future research priorities and collaborative efforts in finding effective drugs or improving treatment outcomes for type 2 diabetes and its complications. However, the study acknowledges the limitations of using a single publication database and recommends that future studies include data from other sources.Keywords: type 2 diabetes,herbal remedies,herbs,bibliometrics,co-occurrence,herbal.

27 February 2026 in Astana Medical Journal
Verified
Journal Article
Open access
PDF file
IKIndira Kaibagarova
Indira Kaibagarova
ASAigul Sartayeva
Aigul Sartayeva
AZAinur Zinalieva
Ainur Zinalieva
AZAkbota Zhumashova
Akbota Zhumashova
КИКайбагарова И.
Кайбагарова И.
ЖАЖумашева А.
Жумашева А.
Background. In routine outpatient care, glycemic control in patients with type 2 diabetes mellitus (T2DM) is influenced by both clinical and behavioral factors. Medication adherence is considered a potentially modifiable determinant of treatment effectiveness; however, its independent association with glycemic outcomes in real-world settings may be difficult to distinguish from the effects of disease duration and patient characteristics. Objective. To examine the association between medication adherence, assessed using the Morisky–Green questionnaire, and HbA1c levels in patients with T2DM. Methods. This analytical cross-sectional pilot study included adult patients with T2DM receiving outpatient care. Medication adherence was assessed using the 8-item Morisky–Green questionnaire and categorized as low, medium, or high. HbA1c levels and clinical variables were obtained from medical records. Differences in HbA1c across adherence categories were evaluated using non-parametric methods. Multivariable linear regression analysis was performed to assess factors associated with HbA1c levels, with additional sensitivity analysis comparing low versus medium/high adherence. Results. HbA1c levels differed significantly across medication adherence categories (Kruskal–Wallis test, p = 0.041). In multivariable analysis, longer diabetes duration was independently associated with higher HbA1c levels (β = 0.24 per year, p = 0.008). Medium/high medication adherence was associated with lower HbA1c values (β = −0.53%), although this association did not reach statistical significance after adjustment. Female sex showed a non-significant trend toward lower HbA1c levels. Conclusions. In patients with T2DM receiving routine outpatient care, diabetes duration represents a key independent determinant of glycemic control. Higher medication adherence is associated with clinically relevant reductions in HbA1c; however, its independent effect may be attenuated in small real-world samples. Keywords: type 2 diabetes mellitus, medication adherence, Morisky–Green questionnaire, HbA1c, real-world data.

30 October 2025 in Наука и здравоохранение
Verified
Journal Article
Open access
AZA.N. Zinalieva
A.N. Zinalieva
GDG.S. Dilmagambetova
G.S. Dilmagambetova
ASAigul Sartayeva
Aigul Sartayeva
ABAkmaral Baspakova
Akmaral Baspakova
DBD.T. Begalina
D.T. Begalina
Maiya TaushanovaMaiya Taushanova
Maiya Taushanova
Asthenia in patients with type 2 diabetes mellitus is a complex and multifaceted phenomenon that affects the physical and psycho-emotional state of patients. This condition of fatigue often arises against the background of chronic hyperglycemia, metabolic disorders, and complications of comorbid diseases. The aim of our study was to examine the susceptibility to asthenia in patients with type 2 diabetes mellitus in the city of Aktobe. Methods. The study design was a cross-sectional clinical study without a control group. The study population consisted of 1,500 patients with type 2 diabetes mellitus registered for follow-up care in state polyclinics of Aktobe, aged 18 to 70 years. To determine the degree of fatigue, the MFI–20 assessment scale was used. Results. The findings indicate a tendency toward deterioration in each of the five indicators of psychophysical health in patients with type 2 diabetes mellitus. When comparing two independent groups, statistically significant differences were found in the indicators of general and physical asthenia (p < 0.01 for each indicator). Conclusions. Patients with type 2 diabetes mellitus are susceptible to asthenia. The highest frequency of general asthenia was observed in patients with a diabetes duration of 5 to 10 years. A higher frequency of general asthenia was found among unemployed patients. Significant differences were established when comparing male and female patients with T2DM in terms of general and physical asthenia. Аннотация. Астения у больных сахарным диабетом 2 типа - сложное и многогранное явление, влияющее на физическое и психоэмоциональное состояние больных. Такое состояние утомления часто возникает на фоне хронической гипергликемии, нарушений обмена веществ и осложнений сопутствующих заболеваний. Целью нашего исследования является изучение подверженности астении пациентов с сахарным диабетом 2 типа г. Актобе. Методы исследования. Дизайн исследования - поперечное клиническое исследование без контрольной группы. Исследуемая популяция состояла из 1500 пациентов с сахарным диабетом 2 типа, находящихся на диспансерном учете в государственных поликлиниках города г. Актобе, в возрасте от 18 до 70 лет. Для определения степени усталости была использована шкала оценки MFI–20. Результаты. Полученные результаты указывают на тенденцию ухудшения в каждом из пяти показателей психофизического состояния здоровья у пациентов с сахарным диабетом 2 типа. При сравнении двух независимых групп статистически значимые различия установлены по показателям общая и физическая астения (p<0,01 для каждого показателя). Выводы. Пациенты с сахарным диабетом 2 типа подвержены астении. Наибольшая частота общей астении имеется у пациентов с длительностью диабета от 5 до 10 лет. Более высокая частота общей астении выявлена среди неработающих пациентов. Значимые различия установлены при сравнении по полу пациентов СД2 к общей и физической астении. Аннотация. 2 -типті қант диабетімен ауыратын науқастардағы астения - науқастың физикалық және психоэмоционалды жағдайына әсер ететін күрделі және көп қырлы құбылыс. Шаршау мен әлсіздіктің бұл күйі жиі созылмалы гипергликемия, метаболикалық бұзылулармен қатар жүретін аурулардың салдарында пайда болады. Біздің зерттеуіміздің мақсаты Ақтөбе қаласындағы 2- типті қант диабетімен ауыратын науқастардың астенияға бейімділігін зерделеу болып табылады. Зерттеу әдістері. Зерттеу дизайны бақылау тобынсыз көлденең қималық клиникалық зерттеу болды. Зерттелетін популяцияны Ақтөбе қаласының мемлекеттік емханаларында есепте тұрған 2 -типті қант диабетімен ауыратын18 бен 70 жас аралығындағы 1500 пациент құрады. Сауалнама жүргізу үшін MFI-20 астенияны бағалау шкаласы қолданылды. Нәтижелер. Алынған нәтижелер 2- типті қант диабетімен ауыратын науқастардың психофизикалық денсаулық жағдайының бес көрсеткішінің әрқайсысында нашарлау үрдісін көрсететті. Екі тәуелсіз топты салыстыру кезінде жалпы және физикалық астения...